Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:20 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,294 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment Response Clear all
Completed Phase 1Phase 2 Interventional

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

NCT00093639
View directory record Official record
Conditions
Leukemia
Interventions
everolimus, imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Nov 1, 2026, 4:20 PM EST
Terminated Not applicable Interventional Results available

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

NCT01799135
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 1, 2026, 4:20 PM EST
Terminated Phase 2 Interventional Results available

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549
View directory record Official record
Conditions
Septic Shock
Interventions
LB1148, Placebo
Drug
Lead sponsor
Leading BioSciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Nov 1, 2026, 4:20 PM EST
Recruiting Not applicable Interventional

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT04221893
View directory record Official record
Conditions
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 1, 2026, 4:20 PM EST
Withdrawn Phase 4 Interventional

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

NCT04741204
View directory record Official record
Conditions
Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 1, 2026, 4:20 PM EST
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Nov 1, 2026, 4:20 PM EST
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 1Phase 2 Interventional

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

NCT00405678
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Training, Chemo only
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 3 Interventional Results available

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Culver City, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 1 Interventional

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

NCT00000725
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 1, 2026, 4:20 PM EST
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Encino, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 1, 2026, 4:20 PM EST
Completed Not applicable Interventional Results available

Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation

NCT04243798
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 1, 2026, 4:20 PM EST
Terminated Phase 2 Interventional Results available

POC Study in Partially Responsive Generalized Anxiety Disorder

NCT02310568
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PF-06372865.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Cerritos, California • Encino, California • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 1, 2026, 4:20 PM EST
Completed No phase listed Observational

Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment

NCT02127918
View directory record Official record
Conditions
Electrical Status Epilepticus in Sleep
Interventions
ESES treated with clobazam
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 2 Interventional

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

NCT00885196
View directory record Official record
Conditions
Moderate and Severe Plaque Psoriasis
Interventions
Placebo, AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
10
States / cities
Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Nov 1, 2026, 4:20 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Symptomatology and Treatment Response in Psychotic Major Depression

NCT00691535
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Nov 1, 2026, 4:20 PM EST
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 1, 2026, 4:20 PM EST
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Nov 1, 2026, 4:20 PM EST
Not listed No phase listed Observational

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

NCT06126263
View directory record Official record
Conditions
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream, Infection, Bacterial, Streptococcal Toxic Shock Syndrome
Interventions
Linezolid, Clindamycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Nov 1, 2026, 4:20 PM EST
Completed No phase listed Observational

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

NCT01457768
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
158
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Nov 1, 2026, 4:20 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

NCT01561989
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
cholecalciferol, questionnaire administration, trivalent influenza vaccine
Dietary Supplement · Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Nov 1, 2026, 4:20 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

NCT03585010
View directory record Official record
Conditions
Anxiety Disorder of Childhood, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder
Interventions
Supportive Parenting for Anxious Childhood Emotions, Parent Educational Support, Cognitive-Behavioral Therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
6 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 1, 2026, 4:20 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734
View directory record Official record
Conditions
HIV Infections
Interventions
Dendritic Cells Pulsed with HIV antigens
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2007 · Synced Nov 1, 2026, 4:20 PM EST